Literature DB >> 10230070

MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.

I Kurkowska-Jastrzebska1, A Wrońska, M Kohutnicka, A Członkowski, A Członkowska.   

Abstract

We have studied MHC class II antigen expression and lymphocytic infiltration during dopaminergic neurone degeneration produced by intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). Microglial activation was observed in the striatum and in the substantia nigra (SN) in this model. We noticed a marked increase of MHC class II antigen expression on microglia and T-cell recruitment in these regions after MPTP treatment. B-lymphocytes were not observed. T-cell infiltration predominantly consisted of CD8+ cells at every time point but CD4+ cells were present too. More than a half of the observed lymphocytes showed strong staining of CD44 antigen. Our findings suggest a possible immune system involvement in the pathological process following MPTP intoxication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230070

Source DB:  PubMed          Journal:  Acta Neurobiol Exp (Wars)        ISSN: 0065-1400            Impact factor:   1.579


  30 in total

1.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 2.  Novel nanomaterials for clinical neuroscience.

Authors:  Jamie L Gilmore; Xiang Yi; Lingdong Quan; Alexander V Kabanov
Journal:  J Neuroimmune Pharmacol       Date:  2008-01-22       Impact factor: 4.147

Review 3.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

Review 4.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 5.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 6.  Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.

Authors:  Ravindran Kumaran; Mark R Cookson
Journal:  Hum Mol Genet       Date:  2015-06-22       Impact factor: 6.150

7.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

8.  Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets.

Authors:  Ashley D Reynolds; David K Stone; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 9.  Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.

Authors:  Katherine E Olson; Howard E Gendelman
Journal:  Curr Opin Pharmacol       Date:  2015-11-11       Impact factor: 5.547

Review 10.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.